Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of the National Comprehensive Cancer Network

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NON. OthmanHAHesham H. Abdel-AalWEWessam A. El-Sherief

Discussion

Loading...

Member takes

Overview

Randomized clinical trial shows olanzapine improves anorexia scores in patients with incurable cancer, suggesting potential benefits for cachexia management.

Key Points

  • Olanzapine treatment led to a median reduction in anorexia scores after one week, unlike placebo, indicating a promising intervention.
  • After 4 weeks, 14% of patients on olanzapine gained significant weight compared to none on placebo, supporting its efficacy.
  • The double-blind, placebo-controlled, randomized clinical trial included 164 participants with incurable cancer and cachexia.
  • Findings highlight the necessity for further research into the long-term safety of olanzapine for managing cancer-associated anorexia.

Cite This Study

Othman et al. (2025) studied this question.

synapsesocial.com/papers/68c19fa854b1d3bfb60db7f3https://doi.org/10.6004/jnccn.2025.7033
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Olanzapine for chemotherapy-related anorexia: Impact on body composition.2026
  2. 2Real-World Analysis of Olanzapine and Functional Outcomes in Outpatient Cancer Rehabilitation2026
  3. 3Investigating the effects of olanzapine on appetite and weight in patients with cancer in a systematic review2026
  4. 4Comparing Olanzapine with Placebo in Patients with Anorexia Nervosa for Increasing BMI and Weight Gain2024
  5. 5Olanzapine for weight gain in children undergoing chemotherapy for solid-organ malignancies: An investigator-initiated, open-label, multicenter, phase III randomized controlled trial (SNOWMAN).2026